Summary
It has recently become possible to generate high-titer papillomavirus-based gene-transfer vectors. The vectors, also known as papillomavirus pseudoviruses (PsV), have been useful for studying papillomavirus assembly, entry, and neutralization, and may have future utility as laboratory gene-transfer tools or vaccine vehicles. This chapter outlines a simple method for production of PsV and their use in a high-throughput papillomavirus neutralization assay. The production method is based on transfection of a 293 cell line, 293TT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudogenome encapsidation within L1/L2 capsids is largely sequence independent, and plasmids entirely lacking PV sequences can be packaged efficiently, provided they are less than 8 kilobases in size. Non-infectious virus-like particles (VLPs) can also be produced after transfection of 293TT cells with L1 alone. Efficient purification of the PsV or VLPs is achieved by Optiprep (iodixanol) density gradient ultracentrifugation. Using these methods, it is possible to produce highly purified PsV with yields of at least 109 transducing units from a single 75-cm2 flask of cells. PsV encapsidating a secreted alkaline phosphatase (SEAP) reporter plasmid were used to develop a high-throughput in vitro neutralization assay in a 96-well plate format. Infection of 293TT cells is monitored by SEAP activity in the culture supernatant, using a highly sensitive chemiluminescent reporter system. Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Meyers, C. and Laimins, L. A. (1994) In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186, 199–215.
Roden, R. B., Greenstone, H. L., Kirnbauer, R., et al. (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70, 5875-5883.
Unckell, F., Streeck, R. E., and Sapp, M. (1997) Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71, 2934–2939.
Touze, A. and Coursaget, P. (1998) In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26, 1317–1323.
Schwartz, S. (2000) Regulation of human papillomavirus late gene expression. Ups J Med Sci 105, 171–192.
Fu, X. Y. and Manley, J. L. (1987) Factors influencing alternative splice site utilization in vivo. Mol. Cell Biol. 7, 738–748.
Andersen, K. J., Vik, H., Eikesdal, H. P., and Christensen, E. I. (1995) Effects of contrast media on renal epithelial cells in culture. Acta Radiol. Suppl. 399, 213–218.
Buck, C. B., Pastrana, D. V., Lowy, D. R., and Schiller, J. T. (2004) Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751–757.
Leder, C., Kleinschmidt, J. A., Wiethe, C., and Muller, M. (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75, 9201–9209.
Pastrana, D. V., Buck, C. B., Pang, Y. Y., et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216.
Buck, C. B., Thompson, C. D., Pang, Y.-Y. S., Lowy, D. R., and Schiller, J. T. (2005) Maturation of papillomavirus capsids. J. Virol. 79, 2839–2846.
Selinka, H. C., Giroglou, T., Nowak, T., Christensen, N. D., and Sapp, M. (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77, 12,961–12,967.
Roden, R. B., Lowy, D. R., and Schiller, J. T. (1997) Papillomavirus is resistant to desiccation. J. Infect. Dis. 176, 1076–1079.
Volkin, D. B., Shi, L., and Sanyal, G. (2002) Stabilized human papillomavirus formulations. U.S. patent 6,358,744 B1.
Joyce, J. G., Tung, J. S., Przysiecki, C. T., et al. (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274, 5810–5822.
Klasse, P. J. and Sattentau, Q. J. (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83, 2091–2108.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Buck, C.B., Pastrana, D.V., Lowy, D.R., Schiller, J.T. (2005). Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays. In: Davy, C., Doorbar, J. (eds) Human Papillomaviruses. Methods in Molecular Medicine, vol 119. Humana Press. https://doi.org/10.1385/1-59259-982-6:445
Download citation
DOI: https://doi.org/10.1385/1-59259-982-6:445
Publisher Name: Humana Press
Print ISBN: 978-1-58829-373-2
Online ISBN: 978-1-59259-982-0
eBook Packages: Springer Protocols